No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson's Disease.

Abstract

The [18F]fluoroethoxybenzovesamicol ([18F]FEOBV) positron emission tomography (PET) ligand targets the vesicular acetylcholine transporter. Recent [18F]FEOBV PET rodent studies suggest that regional brain [18F]FEOBV binding may be modulated by dopamine D2-like receptor agents. We examined associations of regional brain [18F]FEOBV PET binding in Parkinson's disease (PD) subjects without versus with dopamine D2-like receptor agonist drug treatment. PD subjects (n = 108; 84 males, 24 females; mean age 68.0 ± 7.6 [SD] years), mean disease duration of 6.0 ± 4.0 years, and mean Movement Disorder Society-revised Unified PD Rating Scale III 35.5 ± 14.2 completed [18F]FEOBV brain PET imaging. Thirty-eight subjects were taking dopamine D2-like agonists. Vesicular monoamine transporter type 2 [11C]dihydrotetrabenazine (DTBZ) PET was available in a subset of 54 patients. Subjects on dopamine D2-like agonists were younger, had a longer duration of disease, and were taking a higher levodopa equivalent dose (LED) compared to subjects not taking dopamine agonists. A group comparison between subjects with versus without dopamine D2-like agonist use did not yield significant differences in cortical, striatal, thalamic, or cerebellar gray matter [18F]FEOBV binding. Confounder analysis using age, duration of disease, LED, and striatal [11C]DTBZ binding also failed to show significant regional [18F]FEOBV binding differences between these two groups. Chronic D2-like dopamine agonist use in PD subjects is not associated with significant alterations of regional brain [18F]FEOBV binding.

• Authors: Roger L Albin, Prabesh Kanel, Teus van Laar, Sygrid van der Zee, Stiven Roytman, Robert A Koeppe, Peter J H Scott, Nicolaas I Bohnen
• Journal: Molecular pharmaceutics (Mol Pharm) Vol. 19 Issue 4 Pg. 1176-1182 (04 04 2022) ISSN: 1543-8392 [Electronic] United States
• PMID: 35289620 (Publication Type: Journal Article)

Chemical References

• Dopamine Agonists
• Vesicular Acetylcholine Transport Proteins

Topics

• Aged
• Brain (diagnostic imaging, metabolism)
• Dopamine Agonists (metabolism)
• Female
• Humans
• Male
• Middle Aged
• Parkinson Disease (diagnostic imaging, drug therapy, metabolism)
• Positron-Emission Tomography (methods)
• Vesicular Acetylcholine Transport Proteins (metabolism)